Pancreatic ductal adenocarcinoma (PC) is the most common malignant disease in the human pancreas. It is a highly lethal disease and the fourth leading cause of cancer deaths in the US. Fewer than 5% of people with PC live no longer than five years. One of the main reasons it has such a poor prognosis is that the majority of patients already have metastasis at the time of diagnosis, and metastasis makes PC insensitive to many chemotherapeutic drugs including gemcitabine (GEM). Thus, new ways to combat this disease are urgently needed. We discovered that Cyr61/CCN1, an extracellular protein, is overexpressed in PC cells and specimens, and its expression is correlated with disease progression and drug resistance. Moreover, Cyr61 activates sonic hedgehog (SHh) signaling, connective tissue growth factor (CTGF), mutants K-Ras and its activator MAZ/SAF-1-transcription factor in PC cells and stromal cells, all of which contribute to the development of PC as well as drug resistance. Based on these exciting preliminary findings, we now propose to use genetically engineered cell lines, genetically engineered mouse models (GEMMs) along with state-of- the-art technology to unravel if blocking Cyr61 could inhibit PC growth and drug sensitization via blocking desmoplastic reaction in PC. We propose three aims to test the hypothesis.
In Aim 1, we will explore the role of Cyr61 in K-Rasmut mediated PC development and progression using GEMMs and orthotopic transplants of genetically engineered PC cell lines.
In Aim 2, we will examine whether Cyr61 signaling is crucial to maintain stemness and tumorigenic activity of PC-initiating cells (PICs)/stem cells (PSCs) and dissect the down-stream signaling pathway of Cyr61 required to perform these events. Lastly, in Aim 3 we will determine the role of Cyr61 in growth of fibrous tissue (desmoplasia) during PC growth in GEMMs and orthotopic models. To test the aims, we have already standardized the use of an orthotopic human pancreatic cancer xenograft in a SCID mouse model using ultrasound guided injection of PC cells into the pancreas and high resolution imaging techniques. These techniques have already revealed many steps of the progression of this deadly disease, and they will be used along with the unique expertise of our multi-disciplinary collaborative team to explore the role of Cyr61 in pancreatic carcinogenesis. Collectively, these findings will provide knowledge of the essential functions of Cyr61, not only in development of PC, but also the critical role in tumor-stromal interactions for the development of desmoplastic reaction. This knowledge will allow dissection of the molecular mechanisms behind these vital events. Moreover, these studies will directly indicate that disruption of Cyr61-signaling would be a new therapeutic strategy against PC.

Public Health Relevance

Malignant progression of pancreatic cancer from preneoplastic lesions remains a mechanistically unknown event and a major challenge in medical research. By revealing the mechanism of action, this new and substantially different approach aims to demonstrate Cyr61/CCN1 as a positive regulator of pancreatic cancer progression and chemoresistance. We believe that the proposed studies will facilitate the development of novel strategies to prevent or delay the progression of pancreatic cancer.

National Institute of Health (NIH)
Veterans Affairs (VA)
Non-HHS Research Projects (I01)
Project #
Application #
Study Section
Special Emphasis Panel (ONCC)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Kansas City VA Medical Center
Kansas City
United States
Zip Code
Gupta, Vijayalaxmi; Haque, Inamul; Chakraborty, Jinia et al. (2018) Racial disparity in breast cancer: can it be mattered for prognosis and therapy. J Cell Commun Signal 12:119-132
Haque, Inamul; Ghosh, Arnab; Acup, Seth et al. (2018) Leptin-induced ER-?-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway. BMC Cancer 18:99
Ghosh, Arnab; Sarkar, Sandipto; Banerjee, Snigdha et al. (2018) MIND model for triple-negative breast cancer in syngeneic mice for quick and sequential progression analysis of lung metastasis. PLoS One 13:e0198143
Maity, Gargi; Haque, Inamul; Ghosh, Arnab et al. (2018) The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling. J Biol Chem 293:4334-4349
Ghosh, Priyanka; Banerjee, Snigdha; Maity, Gargi et al. (2017) Detection of CCN1 and CCN5 mRNA in Human Cancer Samples Using a Modified In Situ Hybridization Technique. Methods Mol Biol 1489:495-504
Haque, Inamul; Subramanian, Arvind; Huang, Chao H et al. (2017) The Role of Compounds Derived from Natural Supplement as Anticancer Agents in Renal Cell Carcinoma: A Review. Int J Mol Sci 19:
Das, Amlan; Dhar, Kakali; Maity, Gargi et al. (2017) Deficiency of CCN5/WISP-2-Driven Program in breast cancer Promotes Cancer Epithelial cells to mesenchymal stem cells and Breast Cancer growth. Sci Rep 7:1220
Sarkar, S; Ghosh, A; Banerjee, S et al. (2017) CCN5/WISP-2 restores ER-? in normal and neoplastic breast cells and sensitizes triple negative breast cancer cells to tamoxifen. Oncogenesis 6:e340
Hawa, Zuhair; Haque, Inamul; Ghosh, Arnab et al. (2016) The miRacle in Pancreatic Cancer by miRNAs: Tiny Angels or Devils in Disease Progression. Int J Mol Sci 17:
Banerjee, Sushanta K; Maity, Gargi; Haque, Inamul et al. (2016) Human pancreatic cancer progression: an anarchy among CCN-siblings. J Cell Commun Signal 10:207-216

Showing the most recent 10 out of 11 publications